Michael Horberg to HIV Protease Inhibitors
This is a "connection" page, showing publications Michael Horberg has written about HIV Protease Inhibitors.
Connection Strength
0.398
-
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020 04; 23(4):e25484.
Score: 0.177
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
Score: 0.080
-
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis. 2005 Aug 01; 192(3):456-65.
Score: 0.064
-
Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):393-398.
Score: 0.060
-
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1300-5.
Score: 0.018